Patients who have previously experienced xerostomia as a dose-limiting event from PSMA-targeted RPT will particularly benefit from using 177Lu-RM2 if they have high expression of GRPR, since GRPR-targeted RPT has no effect on lacrimal or salivary glands [63]. Here, GRPR is linked to xerostomia.